Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Dietary advanced glycation end products are associated with an increased risk of breast cancer in Iranian adults

Authors: Mitra Kazemi Jahromi, Asal Neshatbini Tehrani, Hossein Farhadnejad, Hadi Emamat, Hamid Ahmadirad, Farshad Teymoori, Zeinab Heidari, Niloufar Saber, Bahram Rashidkhani, Parvin Mirmiran

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Dietary advanced glycation end products (AGEs) can play an important role in increasing inflammatory factors and oxidative stress as risk factors for cancers. In the present study, we aimed to assess the relationship between dietary AGEs and the risk of breast cancer (BC) in Iranian adult women.

Methods

This hospital-based case-control study includes 401 participants aged ≥ 30 years old. The cases group consisted of 134 women diagnosed with histologically confirmed BC. The control group included 267 women enrolled randomly from patients admitted to the same hospitals. Dietary intake information was determined using a validated food frequency questionnaire, and dietary AGEs intake was computed for all participants. Logistic regression models, adjusted for potential confounders, were used to determine the odds ratios (OR) and 95% confidence interval (CI) of BC across tertiles of dietary AGEs.

Results

The mean ± SD age and body mass index of the study population were 47.92 ± 10.33 years and 29.43 ± 5.51 kg/m2, respectively. The median (interquartile) of dietary AGEs in all individuals was 9251(7450, 11,818) kU/day. After adjusting for age, first pregnancy age, and energy intake, participants in the highest tertile of dietary AGEs intakes had higher odds of BC compared to those in the lowest tertile of dietary AGEs (OR:2.29;95%CI:1.19–4.39, Ptrend:0.012). Additionally, in the multivariable model, after adjusting for age, age at first pregnancy, energy, menopausal status, family history of cancer, anti-inflammatory drug use, Vitamin D supplementation, physical activity, body mass index, number of childbirths, and history of abortion, breastfeeding, and oral contraceptive pills use, the odds of BC were increased across tertiles of dietary AGEs intake (OR: 2.33; 95%CI: 1.18–4.60, Ptrend: 0.017).

Conclusion

The present findings suggest that a diet with high AGEs is associated with a higher likelihood of BC in adult women.
Literature
1.
Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries, Cancer J Clin, vol 71, no. 3, pp. 209–49.
2.
Kazeminia M, Salari N, Hosseinian-Far A, Akbari H, Bazrafshan M-R, Mohammadi M. The prevalence of breast Cancer in iranian women: a systematic review and Meta-analysis, Indian J Gynecologic Oncol, vol 20, no. 1, p. 14.
3.
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article, Iran J Public Health, vol 47, no. 3, pp. 309–16.
4.
Sun YS, Zhao Z, Yang ZN et al. Risk factors and preventions of breast Cancer, Int J Biol Sci, vol 13, no. 11, pp. 1387–97.
5.
Abdul-Khalek RA, Abu-Sitta G, El Achi N et al. “Mapping breast cancer journal publications in conflict settings in the MENA region: a scoping review,“ Ecancermedicalscience, vol 14, p. 1129.
6.
Cifu G, Arem H. Adherence to lifestyle-related cancer prevention guidelines and breast cancer incidence and mortality, Ann Epidemiol, vol 28, no. 11, pp. 767 – 73.e1.
7.
De Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and breast Cancer: a Literature Review on Prevention, Treatment and Recurrence, Nutrients, vol 11, no. 7.
8.
Ferrini K, Ghelfi F, Mannucci R, Titta L. “Lifestyle, nutrition and breast cancer: facts and presumptions for consideration,“ Ecancermedicalscience, vol 9, p. 557.
9.
Buja A, Pierbon M, Lago L, Grotto G, Baldo V. “Breast Cancer Primary Prevention and Diet: An Umbrella Review” vol 17, no. 13.
10.
Uribarri J, Woodruff S, Goodman S et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet, J Am Diet Assoc, vol 110, no. 6, pp. 911 – 16.e12.
11.
Poulsen MW, Hedegaard RV, Andersen JM et al. Advanced glycation endproducts in food and their effects on health, Food Chem Toxicol, vol 60, pp. 10–37.
12.
Cai W, Gao Q-d, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction, Mol Med, vol 8, no. 7, pp. 337–46.
13.
Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods, J Am Diet Assoc, vol 104, no. 8, pp. 1287–91.
14.
Uribarri J, del Castillo MD, de la Maza MP et al. Dietary advanced glycation end products and their role in health and disease, Adv Nutr, vol 6, no. 4, pp. 461–73.
15.
Davis KE, Prasad C, Vijayagopal P, Juma S, Adams-Huet B, Imrhan V. Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat, Br J Nutr, vol 114, no. 11, pp. 1797–806.
16.
Uribarri J, Woodruff S, Goodman S et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet, J Am Diet Assoc, vol 110, no. 6, pp. 911–6. e12.
17.
Angoorani P, Ejtahed H-S, Mirmiran P, Mirzaei S, Azizi F. Dietary consumption of advanced glycation end products and risk of metabolic syndrome, Int J Food Sci Nutr, vol 67, no. 2, pp. 170–6.
18.
Mirmiran P, Yousefi R, Mottaghi A, Azizi F. Advanced glycation end products and risk of hypertension in iranian adults: Tehran lipid and glucose study, J Res Med Sci, vol 23, p. 43.
19.
Schröter D, Höhn A. Role of Advanced Glycation End Products in Carcinogenesis and their therapeutic implications, Curr Pharm Design, vol 24, no. 44, pp. 5245–51.
20.
Lee KJ, Yoo JW, Kim YK, Choi JH, Ha T-Y, Gil M. Advanced glycation end products promote triple negative breast cancer cells via ERK and NF-κB pathway, Biochem Biophys Res Commun, vol 495, no. 3, pp. 2195–201.
21.
Omofuma OO, Turner DP, Peterson LL. Dietary Advanced glycation end-products (AGE) and risk of breast Cancer in the prostate, lung, colorectal and ovarian Cancer Screening Trial (PLCO), vol 13, no. 7, pp. 601–10.
22.
Peterson LL, Park S, Park Y, Colditz GA, Anbardar N, Turner DP. “Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the National Institutes of Health-AARP Diet and Health Study,“ Cancer, vol 126, no. 11, pp. 2648-57.
23.
Bellanger M, Zeinomar N, Tehranifar P, Terry MB. Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Global Oncol.
24.
Naja F, Nasreddine L, Awada S, El Sayed Ahmad R, Hwalla N. Nutrition in the prevention of breast Cancer: a middle eastern perspective, Front Public Health, vol 7, p. 316.
25.
Sibai AM, Nasreddine L, Mokdad AH, Adra N, Tabet M, Hwalla N. Nutrition transition and cardiovascular disease risk factors in Middle East and North Africa countries: reviewing the evidence, Annals of Nutrition and Metabolism, vol 57, no. 3–4, pp. 193–203.
26.
Asghari G, Rezazadeh A, Hosseini-Esfahani F, Mehrabi Y, Mirmiran P, Azizi F. Reliability, comparative validity and stability of dietary patterns derived from an FFQ in the Tehran lipid and glucose study, Br J Nutr, vol 108, no. 6, pp. 1109–17.
27.
Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods, Tehran: Nashre Olume Keshavarzy, vol 7, no. 213, pp. 42–58.
28.
Azar M, Sarkisian E. Food composition table of Iran: National Nutrition and food research institute, Shaheed Beheshti University, Tehran.
29.
Aadahl M, Jørgensen T. Validation of a new self-report instrument for measuring physical activity, Med Sci Sports Exerc, vol 35, no. 7, pp. 1196–202.
30.
Ainsworth BE, Haskell WL, Whitt MC et al. Compendium of physical activities: an update of activity codes and MET intensities, Med Sci Sports Exerc, vol 32, no. 9; SUPP/1, pp. S498–S504.
31.
Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review, Int J Behav Nutr Phys Activity, vol 8, no. 1, pp. 1–11.
32.
Garmaroudi GR, Moradi A. Socio-economic status in Iran: a study of measurement index, Payesh (Health Monitor), vol 9, no. 2, pp. 137–44.
33.
Omofuma OO, Peterson LL, Turner DP et al. Dietary Advanced Glycation End-Products and Mortality after Breast Cancer in the Women’s Health Initiative, Cancer Epidemiol Biomarkers Prev, vol 30, no. 12, pp. 2217–26.
34.
Pan S, Guan Y, Ma Y et al. Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling, BMJ Open Diabetes Res Care, vol 10, no. 2.
35.
Walter KR, Ford ME, Gregoski MJ et al. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention, Breast Cancer Res Treat, vol 173, no. 3, pp. 559–71.
36.
Dariya B, Nagaraju GP. Advanced glycation end products in diabetes, cancer and phytochemical therapy, Drug Discov Today, vol 25, no. 9, pp. 1614–23.
37.
Hayyan M, Hashim MA, AlNashef IM. Superoxide Ion: Generation and Chemical Implications, Chem Rev, vol 116, no. 5, pp. 3029–85.
38.
Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions, J Carcinog, vol 5, p. 14.
39.
Liou GY, Storz P. Reactive oxygen species in cancer, Free Radic Res, vol 44, no. 5, pp. 479–96.
40.
Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer, Curr Mol Med, vol 7, no. 8, pp. 777–89.
41.
Sharaf H, Matou-Nasri S, Wang Q et al. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231, Biochim Biophys Acta, vol 1852, no. 3, pp. 429–41.
42.
Nankali M, Karimi J, Goodarzi MT et al. Increased expression of the receptor for Advanced Glycation End-Products (RAGE) is Associated with Advanced breast Cancer Stage, Oncol Res Treat, vol 39, no. 10, pp. 622–8.
43.
Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects, Ann N Y Acad Sci, vol 1043, no. 1, pp. 461–6.
44.
Vlassara H. Advanced glycation in health and disease: role of the modern environment, Ann N Y Acad Sci, vol 1043, no. 1, pp. 452–60.
45.
Nass N, Ignatov A, Andreas L, Weißenborn C, Kalinski T, Sel S. Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases, Histochem Cell Biol, vol 147, no. 5, pp. 625–34.
46.
Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects, Ann N Y Acad Sci, vol 1043, pp. 461–6.
47.
Vlassara H. Advanced glycation in health and disease: role of the modern environment, Ann N Y Acad Sci, vol 1043, pp. 452–60.
48.
Uribarri J, Cai W, Peppa M et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging, J Gerontol A Biol Sci Med Sci, vol 62, no. 4, pp. 427–33.
49.
Palimeri S, Palioura E, Diamanti-Kandarakis E. “Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management,“ Diabetes, metabolic syndrome and obesity: targets and therapy, pp. 415 – 26.
50.
Thompson FE, Subar AF. “Dietary assessment methodology,“ Nutrition in the Prevention and Treatment of Disease, pp. 5–48.
51.
Willett W. Nutritional epidemiology, 3. ; New York: Oxford University Press USA; 2013.
52.
Chen Y, Liu L, Zhou Q et al. Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response meta-analysis with 3,318,796 subjects from 31 cohort studies, BMC Public Health, vol 17, no. 1, p. 936.
53.
Group EHBCC. Body Mass Index, serum sex hormones, and breast Cancer risk in Postmenopausal Women, JNCI: J Natl Cancer Inst, vol 95, no. 16, pp. 1218–26.
54.
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer, N Engl J Med, vol 354, no. 3, pp. 270–82.
Metadata
Title
Dietary advanced glycation end products are associated with an increased risk of breast cancer in Iranian adults
Authors
Mitra Kazemi Jahromi
Asal Neshatbini Tehrani
Hossein Farhadnejad
Hadi Emamat
Hamid Ahmadirad
Farshad Teymoori
Zeinab Heidari
Niloufar Saber
Bahram Rashidkhani
Parvin Mirmiran
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11462-5

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Genome instability-related LINC02577, LINC01133 and AC107464.2 are lncRNA prognostic markers correlated with immune microenvironment in pancreatic adenocarcinoma

Research

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Research

High expression of PPFIA1 in human esophageal squamous cell carcinoma correlates with tumor metastasis and poor prognosis

Research article

Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer

Research

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma

Research

Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits